CZ302808B6 - Vakcína proti sexuálne prenosným nemocem - Google Patents
Vakcína proti sexuálne prenosným nemocem Download PDFInfo
- Publication number
- CZ302808B6 CZ302808B6 CZ20010887A CZ2001887A CZ302808B6 CZ 302808 B6 CZ302808 B6 CZ 302808B6 CZ 20010887 A CZ20010887 A CZ 20010887A CZ 2001887 A CZ2001887 A CZ 2001887A CZ 302808 B6 CZ302808 B6 CZ 302808B6
- Authority
- CZ
- Czechia
- Prior art keywords
- vaccine
- group
- disease
- period
- use according
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 146
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title claims abstract description 9
- 208000019802 Sexually transmitted disease Diseases 0.000 title description 4
- 208000001688 Herpes Genitalis Diseases 0.000 claims abstract description 59
- 201000004946 genital herpes Diseases 0.000 claims abstract description 59
- 239000002671 adjuvant Substances 0.000 claims abstract description 28
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims abstract description 15
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims abstract description 15
- 229940037003 alum Drugs 0.000 claims abstract description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 230000002265 prevention Effects 0.000 claims description 25
- 230000001900 immune effect Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004873 anchoring Methods 0.000 claims description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 25
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 42
- 239000000902 placebo Substances 0.000 description 42
- 201000010099 disease Diseases 0.000 description 26
- 238000002255 vaccination Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 208000009889 Herpes Simplex Diseases 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 10
- 206010048461 Genital infection Diseases 0.000 description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 230000006806 disease prevention Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 206010019973 Herpes virus infection Diseases 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920000056 polyoxyethylene ether Polymers 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 230000002480 immunoprotective effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 206010018072 General signs and symptoms Diseases 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 229940124725 herpes simplex vaccine Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- -1 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 244000000033 sexually transmitted pathogen Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9819898A GB9819898D0 (en) | 1998-09-11 | 1998-09-11 | New vaccine and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ2001887A3 CZ2001887A3 (cs) | 2001-10-17 |
| CZ302808B6 true CZ302808B6 (cs) | 2011-11-23 |
Family
ID=10838766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20010887A CZ302808B6 (cs) | 1998-09-11 | 1999-09-08 | Vakcína proti sexuálne prenosným nemocem |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1109574B1 (https=) |
| JP (1) | JP2002524532A (https=) |
| KR (1) | KR100777896B1 (https=) |
| CN (2) | CN1325311A (https=) |
| AR (1) | AR021798A1 (https=) |
| AT (1) | ATE392214T1 (https=) |
| AU (1) | AU744989B2 (https=) |
| BR (1) | BR9913630A (https=) |
| CA (1) | CA2343399C (https=) |
| CO (1) | CO5090882A1 (https=) |
| CY (1) | CY1108147T1 (https=) |
| CZ (1) | CZ302808B6 (https=) |
| DE (1) | DE69938555T2 (https=) |
| DK (1) | DK1109574T3 (https=) |
| ES (1) | ES2304068T3 (https=) |
| GB (1) | GB9819898D0 (https=) |
| HU (1) | HUP0104297A3 (https=) |
| IL (1) | IL141843A0 (https=) |
| MY (1) | MY122216A (https=) |
| NO (1) | NO329522B1 (https=) |
| NZ (1) | NZ510425A (https=) |
| PL (1) | PL199545B1 (https=) |
| PT (1) | PT1109574E (https=) |
| SI (1) | SI1109574T1 (https=) |
| TR (1) | TR200100948T2 (https=) |
| TW (1) | TWI225790B (https=) |
| WO (1) | WO2000015255A1 (https=) |
| ZA (1) | ZA200101987B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
| GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2630220C (en) | 2005-11-22 | 2020-10-13 | Doris Coit | Norovirus and sapovirus antigens |
| US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| WO2011008400A2 (en) | 2009-06-16 | 2011-01-20 | Novartis Ag | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| AU2011237393B2 (en) | 2010-04-08 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | B-cell antigen presenting cell assay |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| CA2843854A1 (en) | 2011-07-01 | 2013-01-10 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
| US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| JP7525976B2 (ja) * | 2014-07-07 | 2024-07-31 | エリアン リミテッド ライアビリティ カンパニー | ウイルス予防治療方法及び曝露前予防キット |
| BR112018017141A2 (pt) | 2016-02-22 | 2019-01-02 | Boehringer Ingelheim Vetmedica Gmbh | método para a imobilização de biomoléculas |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995017209A1 (en) * | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
| CZ280505B6 (cs) * | 1991-03-21 | 1996-02-14 | Smithkline Beecham Biologicals (S.A.) | Vakcína proti herpes simplex, obsahující HSV glykoprotein D a 3-deacylovaný monofosforyllipid A |
| CZ313497A3 (cs) * | 1995-04-03 | 1998-03-18 | Smithkline Beecham Biologicals S. A. | Vakciny proti Chlamydiím |
| US5776468A (en) * | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
-
1998
- 1998-09-11 GB GB9819898A patent/GB9819898D0/en not_active Ceased
-
1999
- 1999-09-08 CN CN99813127A patent/CN1325311A/zh active Pending
- 1999-09-08 SI SI9931008T patent/SI1109574T1/sl unknown
- 1999-09-08 HU HU0104297A patent/HUP0104297A3/hu unknown
- 1999-09-08 CN CNA2007101469740A patent/CN101130070A/zh active Pending
- 1999-09-08 ES ES99969034T patent/ES2304068T3/es not_active Expired - Lifetime
- 1999-09-08 CZ CZ20010887A patent/CZ302808B6/cs not_active IP Right Cessation
- 1999-09-08 JP JP2000569839A patent/JP2002524532A/ja active Pending
- 1999-09-08 AU AU59752/99A patent/AU744989B2/en not_active Ceased
- 1999-09-08 KR KR1020017003161A patent/KR100777896B1/ko not_active Expired - Fee Related
- 1999-09-08 PL PL346651A patent/PL199545B1/pl not_active IP Right Cessation
- 1999-09-08 AT AT99969034T patent/ATE392214T1/de active
- 1999-09-08 BR BR9913630A patent/BR9913630A/pt not_active Application Discontinuation
- 1999-09-08 EP EP99969034A patent/EP1109574B1/en not_active Expired - Lifetime
- 1999-09-08 CA CA 2343399 patent/CA2343399C/en not_active Expired - Fee Related
- 1999-09-08 NZ NZ51042599A patent/NZ510425A/xx not_active IP Right Cessation
- 1999-09-08 PT PT99969034T patent/PT1109574E/pt unknown
- 1999-09-08 IL IL14184399A patent/IL141843A0/xx not_active IP Right Cessation
- 1999-09-08 WO PCT/EP1999/006623 patent/WO2000015255A1/en not_active Ceased
- 1999-09-08 DE DE1999638555 patent/DE69938555T2/de not_active Expired - Lifetime
- 1999-09-08 DK DK99969034T patent/DK1109574T3/da active
- 1999-09-08 TR TR200100948T patent/TR200100948T2/xx unknown
- 1999-09-09 AR ARP990104534 patent/AR021798A1/es unknown
- 1999-09-09 MY MYPI99003916A patent/MY122216A/en unknown
- 1999-09-10 CO CO99057608A patent/CO5090882A1/es unknown
- 1999-09-14 TW TW88115828A patent/TWI225790B/zh not_active IP Right Cessation
-
2001
- 2001-03-08 NO NO20011193A patent/NO329522B1/no not_active IP Right Cessation
- 2001-03-09 ZA ZA200101987A patent/ZA200101987B/en unknown
-
2008
- 2008-06-18 CY CY081100643T patent/CY1108147T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280505B6 (cs) * | 1991-03-21 | 1996-02-14 | Smithkline Beecham Biologicals (S.A.) | Vakcína proti herpes simplex, obsahující HSV glykoprotein D a 3-deacylovaný monofosforyllipid A |
| US5776468A (en) * | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| WO1995017209A1 (en) * | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
| CZ313497A3 (cs) * | 1995-04-03 | 1998-03-18 | Smithkline Beecham Biologicals S. A. | Vakciny proti Chlamydiím |
Non-Patent Citations (2)
| Title |
|---|
| Apicella M.A. et al.: Current Opinion in Infectious Diseases 1996, 9 (1), str. 52-55; abstrakt * |
| Katz S.L.: Lancet 1997, 350, 1767-70 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6692752B1 (en) | Methods of treating human females susceptible to HSV infection | |
| CA2797937C (en) | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response | |
| CZ302808B6 (cs) | Vakcína proti sexuálne prenosným nemocem | |
| KR20140066160A (ko) | 비경구 노로바이러스 백신 제제 | |
| IL227554A (en) | Vaccines and Compounds against the Streptococcus Pneumoniae Bacteria | |
| Ramírez et al. | Co-administration of Recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity | |
| EP2729158B1 (en) | Vaccines for chlamydia | |
| CA2275896A1 (en) | Chlamydia vaccines | |
| Sacks et al. | Cell-mediated immune responses in owl monkeys (Aotus trivirgatus) with trachoma to soluble antigens of Chlamydia trachomatis | |
| HK1037978B (en) | Vaccine against sexually transmitted diseases | |
| MXPA01002532A (en) | Vaccine against sexually transmitted diseases | |
| AU2932502A (en) | Vaccine against sexually transmitted diseases | |
| Liang | Characterisation of the mucosal immunity in the nasal-associated lymphoid tissue following influenza A virus infection | |
| Farris | Mechanisms of major outer membrane protein (MOMP)-vaccine induced protective immunity against Chlamydia muridarum genital infection | |
| MXPA97007638A (en) | Chlamy vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20130908 |